

Nagaileben Co., Ltd.

7447

Tokyo Stock Exchange Prime Market

22-Nov.-2022

FISCO Ltd. Analyst

Noboru Terashima



FISCO Ltd.

<https://www.fisco.co.jp>

■ Index

■ Summary	01
1. FY8/22 results	01
2. FY8/23 forecasts	01
3. Mid-term management plan	02
■ Company profile	03
■ Business overview	04
1. Sales breakdown	04
2. Sales channels and production status	06
3. Characteristics and strengths	06
4. Company policy (initiatives for CSR)	07
■ Results trends	09
1. Summary of FY8/22 consolidated results	09
2. Financial position	12
3. Cash flow conditions	13
■ Business outlook	14
● FY8/23 consolidated earnings outlook	14
■ Medium- to long-term growth strategy	17
1. Mid-term management plan	17
2. Future business strategies	17
■ Shareholder return policy	20

Summary

FY8/22 ended in line with plan, with sales reaching a record high and operating profit declining 3.5% year on year, within the expected range. In the mid-term management plan, is targeting operating profit of ¥5.5bn in FY8/25

1. FY8/22 results

Nagaileben Co., Ltd. <7447> (hereafter, also “the Company”) is the leading manufacturer in Japan of medical gowns, which is one of its core markets*1, with a domestic market share of over 60%, and it has both a high profit margin and a sound financial condition. In the FY8/22 consolidated results*2, net sales increased 1.0% year on year (YoY) to ¥17,745mn, operating profit decreased 3.5% to ¥5,031mn, recurring profit decreased 3.1% to ¥5,139mn and net profit attributable to the owners of the parent company increased 3.6% to ¥3,778mn due to the recording of extraordinary profit (gain on sales of investment securities). Net sales were in line with the plan and attained a record high. Net sales increased due to the elimination of special demand for the MHLW products (infection prevention products) in FY8/21 and the adoption of the Accounting Standard for Revenue Recognition and other relevant standards from FY8/22, resulting in an increase in sales of only 1.0%. However, net sales increased 2.9%, after excluding these special factors. In terms of profits, although operating profit decreased YoY due to the effect of exchange rates (weakening of the yen), higher raw material prices and the rise in processing fees and logistics costs (use of air transport), we feel this was a good result that is not cause for major concern given that sales were steady and the downturn was in line with expectations.

*1 In the new categories introduced from FY8/21, among its domestic markets, the core markets are those markets in which the Company has comparatively high shares. They correspond to healthcare wear, doctors’ wear, utility and other products, and infection prevention products. There are three markets in the new categories: the core markets, the peripheral markets (patient wear and surgery wear) and the overseas markets.

*2 Effective from FY8/22, the Company has adopted the Accounting Standard for Revenue Recognition and other relevant standards. In addition, year-on-year comparisons have been calculated on the basis of figures prior to application of the accounting standard given that its adoption has a negligible effect on earnings results.

2. FY8/23 forecasts

For FY8/23, the Company forecasts net sales to increase 2.6% YoY to ¥18,200mn, operating profit to decrease 9.1% to ¥4,574mn, recurring profit to decline 9.8% to ¥4,638mn and net profit attributable to owners of the parent company to decline 16.2% to ¥3,164mn. The larger decline in net profit attributable to owners of the parent company was due to the absence of the extraordinary profit recorded in the previous fiscal year. While the Company expects steady growth in sales, it also sees the impact from exchange rates (weakening of the yen) and rising processing fees continuing, and expects operating profits to decline as cost rates rise. In response, the Company plans to enact steps to improve profitability, including price revisions and greater efficiency, but these are not expected to take full effect until 2H and beyond, and it forecasts that 1H results will be the most challenging for the Company.


Summary

3. Mid-term management plan

The Company announced its mid-term management plan, taking into account the results of FY8/22. The plan's numerical targets are net sales of ¥19.3bn and operating profit of ¥5.5bn in FY8/25. The weakening of the yen means exchange rates are currently a headwind, but with sales rising steadily and the Company considering price hikes, we believe it likely that these targets will probably be achieved. There has been no change to the Company's approach for returning profits to shareholders and for FY8/22, it paid an annual dividend of ¥60, and plans to pay the same amount for FY8/23. The Company proactively engages in share buybacks and acquired 612,700 treasury shares (¥1,231mn) in FY8/22 with the objective of enhancing capital efficiency and to respond to the changing management environment. The Company's consistent return to shareholders in this manner is worthy of recognition.

Key Points

- In FY8/22, operating profit decreased, but this was in line with expectations. Mainstay items were steady
- The Company forecasts a 9.1% YoY decline in operating profit for FY8/23, with 1H the most challenging and recovery expected in 2H
- In the mid-term management plan, is targeting operating profit of ¥5.5bn in FY8/25. Is also actively returning profits to shareholders



Source: Prepared by FISCO from the Company's financial results

Company profile

In its core markets, is the leading manufacturer of medical gowns with a domestic market share of over 60%

The Company is a specialist manufacturer of medical gowns for nurses, doctors, patients and others. Established in 1915 as Nagai Shoten, the Company has a rich history. Since then, the Company says it has now expanded its operations nationally to become a leading domestic manufacturer that boasts an annual supply of more than 6.5 million medical gowns a year and a market share of over 60% in one of its core markets of medical gowns for nurses. With regard to the reviewed market categories introduced by the Tokyo Stock Exchange (TSE), the Company shifted its listing to the Prime Market.

History

1915	Mitsuji Nagai started Nagai Shoten, a privately owned business specializing in medical gowns, in Kanda-Jinbocho, Chiyoda-ku, Tokyo.
1941	Ended private business, established Tokyo Eisei Hakui Co. Ltd. together with seven stores in the same industry
1950	Liquidated Tokyo Eisei Hakui Co., Ltd. Mitsuji Nagai and Tatsuro Sawanobori jointly established Nagai Shoten Co., Ltd.
1969	Established a subsidiary, NAGAI UNIFORM INDUSTRY co., Ltd., in Akita Prefecture to expand the medical gowns manufacturing division. Tatsuro Sawanobori was appointed President. Shifted focus of manufacturing and sales business specialization from multipurpose white gowns to medical gowns.
1977	Built second product center in Kameido, Koto-ku, Tokyo. Established a partnership with a US company, G.D. Searle & Company, and established Japan Surgical Apparel Co., Ltd. in Hiroshima City to expand sales of new surgical apparel products for hospitals. Established technology partnerships with Angelica Corp (US) and Toray Industries, Inc. <3402>. Developed and released medical gowns made with a new fabric for leasing.
1979	Changed name to Nagai Co., Ltd.
1980	Opened a sales office in Takamatsu, Kagawa Prefecture. Concluded a license agreement with designer Kansai Yamamoto.
1982	Concluded a license agreement with designer Yukiko Hanai.
1988	Established Emit Co., Ltd. as a spin-off from Nagai Co., Ltd. Thereafter, the two companies exchanged their names, with Emit Co., Ltd. becoming a group management company, and Nagai Co., Ltd. becoming a group headquarters for sales.
1989	Newly built Nagai Luminous, a manufacturing plant for high-grade products, in Akita Prefecture. Started overseas production toward the global division of labor.
1994	Changed name from Nagai Co., Ltd. to Nagaileben Co., Ltd. Built a new logistics center in Akita Prefecture.
1995	Started over-the-counter trading of the Company's stock. Started development and sales of a second pillar product to respond to the aging of society. Vice President Ichiro Sawanobori appointed President.
1996	Concluded a license agreement with French designer Andre Courreges.
1999	Opened a sales office in Nagoya, Aichi Prefecture. Concluded a license agreement with designer Atsuro Tayama.
2001	Listed on the Second Section of the Tokyo Stock Exchange.
2002	Established a technology partnership with Standard Textile Company, Inc. (US) and Toray Industries, Inc. for surgical textiles. Raised the status of the Nagoya sales office to a branch.
2004	Acquired ISO 9001 certification. Listed on the First Section of the Tokyo Stock Exchange. Absorbed Hokkaido Nagai Co., Ltd. and established the Hokkaido branch.
2005	Acquired ISO 14001 certification. Concluded a license agreement with designer Keita Maruyama.
2006	Concluded a brand agreement with designer Minako Yokomori.
2014	Relocated to a new head office building in Kajicho, Chiyoda-ku, Tokyo.
2015	Held a ceremony to commemorate its 100th anniversary.
2016	Transitioned to a company with an Audit & Supervisory Committee.
2017	Concluded a joint development agreement with Shiseido Company, Ltd. <4911>.
2018	Constructed a new sewing center in Daisen City, Akita Prefecture.
2020	Delivered 600,000 articles of PPE garments from protection from COVID-19.
2022	Shifted listing to the Tokyo Stock Exchange Prime Market

Source: Prepared by FISCO from the Company's website and securities report

Business overview


Focusing on expanding sales of highly functional, high-value-added products

1. Sales breakdown

All of the Company's products are medical gowns and related products. The sales composition by item for FY8/22 is 54.7% from healthcare wear, 15.0% from doctors' wear, 3.7% from utility and other products, 0.0% from infection prevention products*, 16.2% from patient wear, 9.1% from surgery wear, and 1.3% from overseas markets.

* The Company added the new category of "infection prevention products" from FY8/20.

Healthcare wear mainly refers to products for nurses, while utility and other products include utility wear (aprons, cardigans, and other garments worn on top of medical gowns and such) and shoes. While profitability does not vary much among the various items, utility and other purchased products have a high percentage of purchased products and relatively low margins. Also, infection prevention products, which were separated into a new segment from FY8/20, are mainly MHLW products, so their profit margin is slightly lower than the average.




Source: Prepared by FISCO from the Company's results briefing materials

Also, in the new categories introduced from FY8/21, the markets are divided into three categories: the core markets where the Company has comparatively high market shares domestically (healthcare wear, doctors' wear, utility and other products, and infection prevention products), the peripheral markets where there is plenty of room to grow in the future (patient wear and surgery wear), and the overseas markets. Regarding the composition of total net sales in FY8/22, the core markets provided 73.4%, the peripheral markets 25.3%, and the overseas markets 1.3%. Net sales were previously disclosed by region, but following the establishment of the new categories, they will no longer be disclosed by region.

Business overview


Net sales composition by market (FY8/22)



Source: Prepared by FISCO from the Company's results briefing materials

The composition of total net sales by product (function) for FY8/22 is 7.2% from high-end products, 57.9% from high-value-added products, 30.7% from value-added products, 4.2% from mass products and 0.0% from MHLW products. On looking at the approximate price-band classifications in nurse wear, mass products are ¥5,000 or less, value-added products are ¥5,000 to ¥7,500, high-value-added products are ¥7,500 to ¥10,000, and high-end products are ¥10,000 or more. The tendency is for higher prices to achieve greater profit margins, so the Company is focusing on expanding sales of high-end products and high-value-added products.

Net sales composition by product (FY8/22)



Source: Prepared by FISCO from the Company's results briefing materials

2. Sales channels and production status

The Company's end users include nurses and doctors, with the purchasers of the products mainly being medical facilities such as hospitals, nursing care facilities, and other such facilities. However, the Company does not conduct direct sales, with 100% of sales being agency sales via wholesalers that sell to these medical and other facilities. As a result, sales expenses are kept down, but the Company is still able to understand customers' needs as the sales staff is constantly in contact with large hospitals and other facilities.

In the past, medical gowns were laundered in-house by the hospitals themselves in most cases, but in recent years, they have been switching to leasing alongside the spread in laundry outsourcing. The lease term is typically four years. Because this generates lease renewal demand every four years, it seems to stably support the Company's earnings. However, the lease renewal cycle does not necessarily occur in the same time period as the previous time and there are cases of it being slightly before or after, so sometimes a slight shifting occurs for the net sales (YoY) for each quarter.

Looking at the Company's production structure, based on FY8/22 results (non-consolidated), internal production and at partner plants constitute an aggregate of 99.2% (47.3% domestically and 51.9% overseas), with purchased products accounting for 0.8%. Overseas production takes place in Indonesia, Vietnam, and China, but the Company owns no plants and the goods are produced at the plants of its local partners, which mitigates investment risk and reduces costs.

3. Characteristics and strengths

The Company is a specialized manufacturer of medical gowns, and one of its strengths is that it has in place an integrated system to undertake every aspect of this business, from planning through to raw material procurement, manufacturing, and sales. In its product planning, it can accurately understand customer needs and reflect them in its products. Specifically, the Company sells products that are easy to work in (easy to move around) while incorporating antistatic, antibacterial (restricting the spread of bacteria), and other functions, as well as featuring excellent designs, and they have earned excellent reputations among their users. At the same time, it deals directly with major synthetics manufacturers and textiles traders, including Toray Industries, Inc. <3402>, with which it is jointly developing materials, so it is able to secure optimal materials and produce at low costs while selling them at appropriate margins.

Furthermore, in addition to its large number of affiliated plants, the Company has the necessary financial resources to be able to constantly maintain product item inventories that extend into the thousands of varieties and respond to needs for made-to-order products. It has established a quick response (QR) system of rapid production and sales that delivers the desired product on a specified day in response to a broad range of users. This has also helped in earning the strong trust of its customers. On the sales side, the Company has a network of close to 1,000 agents nationwide, and while its sales capabilities are robust, the Company itself keeps sales expenses as low as possible.

As a result, the Company's share in one of its core markets of medical gowns, the domestic market for medical gowns exceeds 60.0%, and it maintains a firm position as the leading medical gown manufacturer in Japan. Additionally, it is maintaining high profitability with a gross profit margin of 44.4% (actual results for FY8/22). The fact that it is both highly profitable and has a high market share demonstrates that most of its customers are satisfied with its products and services, which is the Company's greatest strength.

Business overview

By concentrating its business resources in the niche market of medical gowns, the Company can efficiently manage every aspect of its business, from planning through to manufacturing and sales. Although it is a niche market, there remains room for further development, as the Company has relatively low shares of the peripheral markets for patient wear, surgery wear, and other items. The Company has explicitly stated that the medical gown business could grow for some time and that it will take active steps to develop the peripheral markets.

4. Company policy (initiatives for CSR)

The Company commemorated its centennial in 2015 by cultivating “Nagaism,” the company spirit, which is focused on realizing interpersonal harmony, generating profits, and contributing to society. It has undertaken the following specific initiatives for CSR.

“We want to become the power of life” at the core of initiatives

(1) Expanding women’s roles: Supporting industries led by women

Many of the Company’s products are for women working on the front lines at hospitals and nursing care facilities, and its production facilities have many women involved in sewing work. The Company’s business operations create many opportunities to expand the roles of women from a variety of life stages, which connects to supporting working women.

(2) Contributing to customers

a) Opened the ITONA gallery, an oasis for nurses

The ITONA gallery, Japan’s first communication space for nurses, was opened in 2015 to celebrate the Company’s 100th anniversary and as a gesture of gratitude to nurses, the Company’s main end users.

b) Beauty courses for nurses

With the cooperation of Shiseido Japan Co., Ltd., the Company is providing practical courses, including learning about make-up and personal behavior that are suitable for nurses in the medical industry. From FY8/22, the Company will go online, offering online beauty courses and beauty advice movies.

c) Remake of student nurses’ uniforms

The Company has deconstructed the training uniforms of student nurses at Okayama University and remade them into pouches, so that they can use them even after starting work at medical facilities.

(3) Contributing to communities

a) Medical kids project

This project started from the idea of deepening interaction between hospitals and local communities and enabling children to attend hospitals or undergo hospitalization with ease of mind. Child-sized medical gowns resembling those worn by doctors and nurses are lent to hospitals and people dressed as characters make hospital visits.

b) Lending of historical gowns

Together with the changes to gowns, the Company lends gowns free of charge, such as to the events of medical facilities, with the objective of understanding the history of nurses.

c) Contributing to communities through production sites

The Company is creating employment and contributing to regional economies through its production operations in Akita Prefecture in Japan, and in China, Indonesia, Vietnam, and elsewhere overseas.

Business overview

d) Provision of uniforms to nurses providing support after disasters

In a new initiative launched in FY8/22, the Company provided the Japanese Nursing Association with uniforms to be worn by nurses dispatched to different regions in the event of a disaster, and also provided the nursing associations of each prefecture with uniforms for storage and stockpiling.

Social responsibility initiatives**(4) Environment****a) Reducing environmental burden through business**

Many of the Company's products use materials derived from depletable resources and it believes that by planning, manufacturing and selling products that can be used repeatedly and for a long time is effective use of limited resources, which will lead to reducing environmental burden. Specifically, the Company acquired ISO 14001 certification in 2005, and carries out initiatives such as using cutting wastage from raw materials for roofing processing and other purposes. The Company has also developed and sells COMPELPACK, a reusable infection prevention product for use on surgical front lines. By providing wear that can be repeatedly washed and sterilized, converting it to reusable products instead of being disposable, it is contributing to the reduction of medical waste. Other initiatives include introducing hybrid vehicles for use as sales vehicles and installing solar power generating panels on the headquarters building.

b) Response to climate change problems

The Company plans mitigation and adaptation initiatives for climate change problems, identification of opportunities and risks, etc., and implementation of a decision-making process toward scenario analysis as a climate change disclosure in accordance with the TCFD (Task Force on Climate-related Financial Disclosure).

(5) Social contribution**a) Donations of new infection prevention products to medical entities and others**

In the fight against COVID-19, the Company donated 40,000 reusable masks and 10,000 reusable isolation gowns. It is also continuously conveying messages of support to medical personnel and the Company regularly publishes a poetry collection for nurses, which are given free of charge to hospitals and nurses.

b) Promotion of the employment of persons with disabilities

Subsidiary Nagai Uniform Industry Co., Ltd. was awarded by the Minister of Health, Labour and Welfare in September 2016 after being selected as an excellent business that contributes to the active employment and promotion of persons with disabilities.

c) Disaster support activities

The Company has provided monetary donations, medical gowns, masks, wheelchairs and other items through the Japanese Nursing Association and the Japanese Red Cross Society following the outbreak of SARS and natural disasters including the Indonesian earthquake, the Great Hanshin Earthquake, the Great East Japan Earthquake, the Kumamoto earthquakes, and the COVID-19 pandemic.

d) Published in Future Class

The Company's initiatives are introduced in Future Class, which is a teaching material used in classes on SDGs (Sustainable Development Goals) that is distributed to elementary and junior high schools nationwide.

Business overview

e) Other assistance

The Company supports the United Nations' World Food Programme (WFP), an agency that provides food assistance. Additionally, it supports the Minamisanriku Reconstruction Sakura Tree Planting effort and is cooperating with volunteers from Minamisanriku Town (Miyagi Prefecture), an area affected by the Great East Japan Earthquake, on the "Forest of Life with a View of the Ocean" initiative to plant Sakura (cherry blossom) trees in locations reached by the tsunami. Representative Director and President Ichiro Sawanobori is also serving as the Industrial Ambassador for Misato Town (Akita Prefecture). In addition, the Company serves as an official supporter of the Para-Art Activity promoted by the Nippon Charity Kyokai to support the disabled.

Results trends

In FY8/22, operating profit decreased 3.5% YoY, but this was in line with expectations. Mainstay items were steady

1. Summary of FY8/22 consolidated results

In FY8/22 consolidated results, net sales increased 1.0% YoY to ¥17,745mn, operating profit decreased 3.5% to ¥5,031mn, recurring profit decreased 3.1% to ¥5,139mn, and net profit attributable to the owners of the parent company increased 3.6% to ¥3,778mn due to the recording of extraordinary profit (gain on sales of investment securities).

The Company maintained an increase in net sales thanks to a steady influx of renewal projects, despite the elimination of ¥315mn in special projects for the MHLW. In terms of profit and loss, operating profit decreased due to the impact of exchange rates (weakening of the yen), higher raw material prices and processing fees, as well as higher logistics costs (use of air transport), but these factors were anticipated from the beginning of the fiscal year and results were within the expected range. While operating profit declined, sales remained steady, and we at FISCO consider this a healthy result overall.

Summary of FY8/22 consolidated results

	FY8/21		FY8/22		Change	
	Results	% of total	Results	% of total	Amount	Percentage
Net sales	17,563	100.0%	17,745	100.0%	182	1.0%
Gross profit	8,058	45.9%	7,881	44.4%	-176	-2.2%
SG&A expenses	2,846	16.2%	2,850	16.0%	3	0.1%
Operating profit	5,212	29.7%	5,031	28.4%	-180	-3.5%
Recurring profit	5,306	30.2%	5,139	29.0%	-166	-3.1%
Net profit attributable to the owners of the parent company	3,647	20.8%	3,778	21.3%	130	3.6%

Note: Effective from FY8/22, the Company has adopted the Accounting Standard for Revenue Recognition and other relevant standards. Moreover, comparative information has been calculated using numerical values prior to application of such accounting standards when it comes to respective figures for FY8/21 as well as increases and decreases

Source: Prepared by FISCO from the Company's financial results

Results trends

In the market environment, while medical frontline operations have not completely recovered, they have emerged from a period of disruption and have regained a measure of stability. In addition, authorities increased medical fees by 0.43% and decreased drug prices by 1.37% per their revision of medical fees effective from April 2022, and average wages for nurses and care staff were also increased (by 1% from February 2022, and 3% in October), but these changes are not expected to have a significant impact on orders for the Company's products.

In net sales in its core markets, the Company brought in a steady influx of scheduled renewal projects and new projects, primarily around high value-added products in its mainstay healthcare wear and doctors' wear segments. In peripheral markets, the Company worked to expand sales of patient wear, a strong performer, and in overseas markets focused on acquiring large-scale projects in Taiwan. As a result, sales increased by 1.0% YoY, ending up 0.3% above plan for a record high.

In profits, the gross profit margin decreased 1.5pp to 44.4%, and gross profit decreased 2.2% to ¥7,881mn. Factors behind the change in gross profit included a ¥83mn increase in sales and a decline of ¥260mn due to a decrease in profit margin. Further analysis of the factors contributing to the decline in profit margin reveals a ¥202mn decrease due to the impact of exchange rates (weakening of the yen, from ¥104.3/US\$ in FY8/21 to ¥114.1/US\$ in FY8/22); a ¥51mn decrease due to the impact of rising processing fees; and a decrease of ¥73mn due to the impact of rising overseas logistics costs (cost of sales) associated with the global disruption of logistics networks (with air mail used for transport of some materials, etc. in response to customer requests). At the same time, there was an increase of ¥60mn due to the effect of a higher overseas production ratio (50.7% in FY8/21 versus 51.9% in FY8/22).

Meanwhile, SG&A expenses increased by 0.1% YoY, to ¥2,850mn. While transportation costs rose by ¥23mn with the recovery in business activities both domestically and overseas, expenses were down 1.1% versus plan due to a decrease in advertising costs (¥14mn) and cuts in other expenses. As a result, operating profit decreased 3.5% YoY to ¥5,031mn, an increase of 0.4% above plan. Capital investments totaled ¥218mn (building and property-related ¥137mn, IT facilities ¥32mn, logistics facilities ¥28mn, production facilities ¥21mn) and depreciation was ¥283mn.

(1) Net sales by item and market

In core markets, net sales declined just 1.4% YoY to ¥13,021mn due to steady renewal of scheduled projects in 2H and the acquisition of new projects. By item, healthcare wear grew 1.4% YoY to ¥9,698 and doctors' wear grew 2.1% to ¥2,655mn. Meanwhile, sales of utilities and others (utility wear, shoes, etc.) and infection prevention products declined, but the impact on overall sales was minor due to the small amounts involved. Sales in peripheral markets, where the company is focusing its efforts, grew steadily, with net sales up 8.0% to ¥4,486mn, which is worthy of recognition. By item, patient wear grew 14.2% YoY to ¥2,872mn, while surgical wear declined 1.5% to ¥1,614mn. In overseas markets, net sales were up 16.7% to ¥237mn with the acquisition of large-scale projects.

Results trends

Net sales by item and market

(¥mn)

	FY8/21		FY8/22	
	Results	YoY	Results	YoY
Core markets	13,207	0.7%	13,021	-1.4%
Healthcare wear	9,560	8.2%	9,698	1.4%
Doctors' wear	2,600	6.1%	2,655	2.1%
Utility and other products	685	-4.2%	662	-3.3%
Infection prevention products	361	-67.7%	5	-98.6%
Peripheral markets	4,152	10.8%	4,486	8.0%
Patient wear	2,514	22.0%	2,872	14.2%
Surgery wear	1,638	-3.0%	1,614	-1.5%
Overseas markets	203	0.9%	237	16.7%
Total	17,563	2.9%	17,745	1.0%

Note: Effective from FY8/22, the Company has adopted the Accounting Standard for Revenue Recognition and other relevant standards. Moreover, comparative information has been calculated using numerical values prior to application of such accounting standards when it comes to respective figures for FY8/21
 Source: Prepared by FISCO from the Company's results briefing materials

(2) Net sales by product

In high-end products, the Company focused on strengthening its Elegance product line, and net sales increased 4.2% YoY to ¥1,269mn. In high value-added products, it made progress catching up on renewal projects, and net sales rose 10.4% to ¥10,269mn. In January 2022, the Company launched sales of EARTH SONG, a new brand concept. Sales of value-added products fell 8.6% YoY to ¥5,452mn, in part due to the high level of sales in the previous fiscal year. Mass products were down 1.5%, to ¥752mn, but these involved non-focus products and small amounts and the overall impact was minor.

Net sales by product

(¥mn)

	FY8/21		FY8/22	
	Results	YoY	Results	YoY
High-end products	1,218	13.6%	1,269	4.2%
High-value-added products	9,302	7.0%	10,269	10.4%
Value-added products	5,963	6.5%	5,452	-8.6%
Mass products	764	1.1%	752	-1.5%
MHLW products	315	-66.7%	0	-100.0%
Total	17,563	2.9%	17,745	1.0%

Note: Effective from FY8/22, the Company has adopted the Accounting Standard for Revenue Recognition and other relevant standards. Moreover, comparative information has been calculated using numerical values prior to application of such accounting standards when it comes to respective figures for FY8/21

Source: Prepared by FISCO from the Company's results briefing materials

Results trends

Financial position remains sound given a high level of cash and deposits on hand at ¥28.5bn, and an equity ratio of 89.2%

2. Financial position

The Company's financial position remains stable. At the end of FY8/22, total assets had increased by ¥919mn to ¥47,347mn compared to the end of the previous fiscal year. Current assets increased by ¥1,579mn to ¥38,902mn, mainly due to an increase in cash and deposits of ¥681mn, an increase in notes and accounts receivable including electronically recorded claims of ¥464mn, and an increase in inventories of ¥270mn. Meanwhile, fixed assets decreased by ¥660mn to ¥8,445mn, mainly due to a decrease in tangible fixed assets of ¥107mn from depreciation and a decrease in investments and other assets of ¥566mn as a result of a decrease in investment securities.

Total liabilities were ¥5,092mn, up ¥693mn compared to the end of the previous fiscal year. This was largely attributable to an increase of ¥317mn in notes and accounts payable and an increase of ¥109mn in income taxes payable. Net assets increased ¥225mn to ¥42,255mn, mainly due to a ¥743mn decrease in retained earnings from payment of dividends. As a result, the equity ratio was 89.2% at the end of FY8/22, down 1.3pp compared to the end of the previous fiscal year.

Summary of the consolidated balance sheet

	(¥mn)		
	End of FY8/21	End of FY8/22	Change
Cash and deposits	27,879	28,560	681
Notes and accounts receivable (including electronically recorded claims)	4,775	5,239	464
Inventories	4,615	4,886	270
Current assets	37,322	38,902	1,579
Tangible fixed assets	7,489	7,381	-107
Intangible fixed assets	43	56	13
Investments and other assets	1,572	1,006	-566
Fixed assets	9,106	8,445	-660
Total assets	46,428	47,347	919
Notes and accounts payable	1,290	1,607	317
Income taxes payable	945	1,055	109
Total liabilities	4,399	5,092	693
Retained earnings	43,276	42,532	-743
Treasury shares	-5,913	-4,151	1,762
Net assets	42,029	42,255	225
Total liabilities and net assets	46,428	47,347	919

Source: Prepared by FISCO from the Company's financial results

Results trends

3. Cash flow conditions

In FY8/22, cash flow provided by operating activities increased ¥3,442mn. The main factors were the recording of profit before income taxes, etc. of ¥5,468mn, depreciation of ¥283mn, an increase in accounts payable of ¥317mn, an increase in trade receivables of ¥478mn and an increase in inventories of ¥270mn. Cash flow used in investing activities decreased ¥471mn. The main factors included proceeds from sales of investment securities of ¥527mn, acquisition of tangible fixed assets of ¥94mn and increase in fixed deposits (net) of ¥900mn. Cash flow used in financing activities decreased ¥3,202mn, with the main items being dividend payments of ¥1,971mn and purchase of treasury shares of ¥1,231mn. As a result, cash and cash equivalents during the period decreased ¥218mn and the balance of cash and cash equivalents at the end of the period was ¥5,460mn. The Company has no interest-bearing debt and owns treasury shares worth ¥4,151mn (3,475,817 shares), so as before, it possesses an abundance of liquidity on hand.

Note that while the Company acquired 612,700 treasury shares (for a total purchase price of ¥1,231mn), it has also cancelled 2,500,000 treasury shares (6.54% of total shares issued prior to the cancellation).

Summary of the consolidated statement of cash flows

	(¥mn)	
	FY8/21	FY8/22
Cash flow from operating activities	4,448	3,442
Profit before income taxes, etc.	5,288	5,468
Depreciation	316	283
Change in trade receivables (negative is an increase)	890	-478
Change in inventories (negative is an increase)	16	-270
Change in accounts payable (negative is a decrease)	-302	317
Cash flow from investing activities	-3,255	-471
Payments to acquire tangible fixed assets	-238	-94
Change in fixed deposits (net)	-3,000	-900
Sale of investment securities	-	527
Cash flow from financing activities	-1,971	-3,202
Payment of dividends	-1,971	-1,971
Payment to acquire treasury shares	-0	-1,231
Change in cash and cash equivalents	-767	-218
Balance of cash and cash equivalents at period end	5,679	5,460

Source: Prepared by FISCO from the Company's financial results

Business outlook

Facing severe cost factors, operating profit is expected to decline by 9.1% in FY8/23, but is forecast to recover in 2H due to the effects of price revisions, etc.

● FY8/23 consolidated earnings outlook

For its FY8/23 consolidated results, the Company is forecasting net sales to increase 2.6% YoY to ¥18,200mn, operating profit to decrease 9.1% to ¥4,574mn., recurring profit to decline 9.8% to ¥4,638mn, and net profit attributable to owners of the parent company to fall 16.2% to ¥3,164mn. The decrease in net profit attributable to owners of the parent company is larger due to the absence of extraordinary profit recorded in the previous fiscal year.

While the Company expects steady growth in sales, it also sees continuing impact from exchange rates (weakening of the yen) and rising processing fees, and expects operating profits to decline as cost rates rise. In response, the Company plans to enact steps to improve profitability, including price revisions and greater efficiency, but these are not expected to take full effect until 2H and beyond, and it forecasts that 1H results will be the most challenging for the Company.

FY8/23 consolidated earnings outlook

	FY8/22		FY8/23		Change	
	Results	% of total	Forecast	% of total	Amount	Percentage
Net sales	17,745	100.0%	18,200	100.0%	454	2.6%
Gross profit	7,881	44.4%	7,618	41.9%	-263	-3.3%
SG&A expenses	2,850	16.0%	3,044	16.7%	194	6.8%
Operating profit	5,031	28.4%	4,574	25.1%	-457	-9.1%
Recurring profit	5,139	29.0%	4,638	25.5%	-501	-9.8%
Net profit attributable to the owners of the parent company	3,778	21.3%	3,164	17.4%	-613	-16.2%

Source: Prepared by FISCO from the Company's financial results and results briefing materials

In terms of net sales, in its core market the Company will push to the fore EARTH SONG, its new brand concept launched in FY8/22, in an effort to invigorate the market while ensuring it receives orders for new projects and increases market share. In the peripheral markets, the Company aims to introduce and expand sales of new products in patient wear, a strong performer. In overseas markets, it will develop new sales channels, launching direct e-commerce sales in Taiwan. With these steps, it plans to increase sales across all markets, and aims to achieve record-high sales overall.

Business outlook

On the other hand, the Company expects the profit situation to remain challenging. Due to the weaker-than-expected yen exchange rate, gross profit margin is projected to be 41.9% (versus 44.4% the previous fiscal year), with gross profit of ¥7,618mn (down 3.3% YoY), with an increase of ¥202mn due to the higher sales factor but a decrease of ¥466mn due to lower profit margins. Factors expected to reduce profit margins include a ¥460mn decrease due to the exchange rate (weakening of the yen—expected to be about ¥135.0/US\$ in FY8/23, covered by forward contracts, compared to ¥114.1/US\$ in FY8/22); a decrease of ¥78mn due to a rise in processing fees, including overseas; and an increase of ¥60mn due to an increase in the overseas production ratio (forecast at 53.0% in FY8/23 versus 51.9% in FY8/22). Also, because of concerns over a further rise in raw material expenses, the Company expects profits to decline by ¥230mn. At the same time, the Company expects logistics costs to fall with a decline in the use of air transport, greater efficiency and other improvements to profitability, contributing ¥30mn to increased profits, along with a ¥212mn increase from price revisions.

The Company predicts the impact of the COVID-19 pandemic will diminish and markets will move toward greater stability. In terms of expenses, it expects transportation expenses to increase by ¥28mn and advertising expenses by ¥78mn as sales activities are expected to return to normal, resulting in a 6.8% YoY increase in SG&A expenses to ¥3,044mn. As a result, the Company expects operating profit to decline 9.1% to ¥4,574mn. Note that it expects capital investments to total ¥325mn (building and property-related ¥127mn, IT facilities ¥107mn, logistics facilities ¥60mn, production facilities ¥30mn) with depreciation of ¥301mn, both within normal range.

As noted above, the outlook for FY23/8 results is extremely challenging, but the situation will differ slightly between 1H and 2H. In response to various cost increases, the Company plans to improve profitability through price revisions and greater efficiency, but the effects of those price revisions are not expected to become apparent until 2H. This is why results in 1H of FY8/23 are expected to be the most difficult, while 2H will see a recovery trend.

FY8/23 results forecast (1H/2H)

	FY8/22		FY8/23		
	Results	Profit margin	Forecast	Profit margin	YoY
Net sales	17,745	-	18,200	-	2.6%
1H	7,817	-	8,022	-	2.6%
2H	9,928	-	10,178	-	2.5%
Gross profit	7,881	44.4%	7,618	41.9%	-3.3%
1H	3,491	44.7%	3,329	41.5%	-4.7%
2H	4,389	44.2%	4,289	42.1%	-2.3%
Operating profit	5,031	28.4%	4,574	25.1%	-9.1%
1H	2,035	26.0%	1,719	21.4%	-15.6%
2H	2,995	30.2%	2,855	28.1%	-4.7%

Source: Prepared by FISCO from the Company's financial results and results briefing materials

(1) Net sales forecasts by item and market

In net sales by market, sales are forecast to increase across all markets. Net sales in core markets are expected to increase 1.4% YoY to ¥13,200mn. By item, the Company plans for a 1.6% increase in healthcare wear, to ¥9,850mn, a 1.7% increase in doctors' wear, to ¥2,700mn, and a 6.4% decrease in others to ¥620mn, with infection prevention products increase 477.3% to ¥30mn. It expects a 5.9% increase in peripheral markets, to ¥4,750mn, with patient wear up 7.9% to ¥3,100mn and surgical wear up 2.2% to ¥1,650mn. It also forecasts a 5.5% increase in overseas markets, to ¥250mn.

Business outlook

Net sales forecasts by item and market

(¥mn)

	FY8/22		FY8/23	
	Results	YoY	Forecast	YoY
Core markets	13,021	-1.4%	13,200	1.4%
Healthcare wear	9,698	1.4%	9,850	1.6%
Doctors' wear	2,655	2.1%	2,700	1.7%
Utility and other products	662	-3.3%	620	-6.4%
Infection prevention products	5	-98.6%	30	477.3%
Peripheral markets	4,486	8.0%	4,750	5.9%
Patient wear	2,872	14.2%	3,100	7.9%
Surgery wear	1,614	-1.5%	1,650	2.2%
Overseas markets	237	16.7%	250	5.5%
Total	17,745	1.0%	18,200	2.6%

Source: Prepared by FISCO from the Company's results briefing materials

(2) Net sales forecasts by product

In high-end products, the Company plans to increase sales by 2.4% YoY, to ¥1,300mn, by focusing on strengthening its Elegance product line. In high value-added products, it will pursue higher added value through market penetration of its new EARTH SONG brand concept, with sales expected to increase 4.2% to ¥10,700mn. The Company plans to increase sales of value-added products by 0.9%, to ¥5,500mn, by capturing projects from other companies and promoting a shift from mass-market to value-added products.

Net sales forecasts by product

(¥mn)

	FY8/22		FY8/23	
	Results	YoY	Forecast	YoY
High-end products	1,269	4.2%	1,300	2.4%
High-value-added products	10,269	10.4%	10,700	4.2%
Value-added products	5,452	-8.6%	5,500	0.9%
Mass products	752	-1.5%	700	-7.0%
MHLW products	0	-100.0%	-	-
Total	17,745	1.0%	18,200	2.6%

Source: Prepared by FISCO from the Company's results briefing materials


■ Medium- to long-term growth strategy

Mid-term management plan targets operating profit of ¥5.5bn in FY8/25

1. Mid-term management plan

The Company previously announced a mid-term management plan ending in FY8/24 when it announced its FY8/21 results, but based on its FY8/22 results, subsequently announced a plan that would carry over from the previous mid-term management plan. The plan sets out numerical targets for FY8/25 net sales of ¥19.3bn and operating profit of ¥5.5bn*. It also expects gross profit margin to bottom out in FY8/23, before gradually improving with the effects of price revisions and other moves. The Company plans for gross profit margin to recover to 44.5% by FY8/25, the final year of the plan.

* Assumes an exchange rate of ¥125 (fixed).




Note: Planned figures for FY8/24 are estimates calculated by FISCO
 Source: Prepared by FISCO from the Company's financial results and results briefing materials

2. Future business strategies

The COVID-19 pandemic is currently affecting the Company's business environment, but could be a medium- to long-term tailwind. According to data released by MHLW among others, the number of nurses in Japan is projected to increase from 1.68 million in FY2019 to a maximum of 2.02 million in FY2025. Moreover, the number of demanded nursing care professionals is forecast to increase from 1.86 million in FY2020 to 2.45 million in FY2025.

Medium- to long-term growth strategy




Source: Prepared by FISCO from the following materials (English titles have been translated from Japanese)
 FY2019 Actual Number of Nursing Professionals from "Statistical Data on Nursing Service in Japan" (Japanese Nursing Association)
 FY2025 Estimated Number of Nursing Professionals from "Study Group on Supply and Demand of Medical Personnel" Materials (MHLW)
 FY2020 Actual Number of Nursing Care Professionals from "Survey of Institutions and Establishments for Long-Term Care" (MHLW)
 FY2025 Estimated Number of Nursing Care Professionals from "7th Nursing Care Insurance Business Group Plan" (MHLW)

In this sort of business environment, the Company plans to achieve growth in the medium term through the following three strategies: (1) market strategy to expand sales, (2) product strategy to stabilize profitability, (3) and production strategy to improve the profit margin.

(1) Market strategy to expand sales

As its market strategy, the Company is aiming to expand sales not only in its core markets in which it has comparatively high shares, but also by further deepening its businesses in the peripheral markets that still have plenty of room to grow in the future. For the overseas markets, the Company is developing markets, mainly in South Korea and Taiwan, by utilizing the business model that is one of its strengths. By implementing these strategies, it forecasts that the net sales composition by market in FY8/25 will be 70% from the core markets (compared to 78% in FY8/19), 28% from the peripheral markets (21%), and 2% from the overseas markets (1%).


Medium- to long-term growth strategy



Source: Prepared by FISCO from the Company's results briefing materials

(2) Product strategy to stabilize profitability

As its product strategy, the Company will aim to progress sales growth of high-end products and high-value-added products, and at the same time make an effort to increase sales of mass products and value-added products. Its policy is to stabilize profitability even further. As a result, it is forecasting that the composition of net sales by product in FY8/25 will be 9% from high-end products (compared to 7% in FY8/19), 60% from high-value-added products (51%), 28% from value-added products (36%), and 3% from mass products (5%).




Source: Prepared by FISCO from the Company's results briefing materials

Medium- to long-term growth strategy

(3) Production strategy to improve the profit margin

As its production strategy, the Company intends to improve the profit margin by raising the overseas production ratio through shifting production overseas, while keeping down exchange rate-related risk. In Japan, its policy is to maintain a high profit margin by strengthening its ability to respond to requests for QR and multiple-product, small lot production runs. By implementing these strategies, it is forecasting that the composition of total production in FY8/25 will be 55% from overseas production (compared to 52% in FY8/19), 44% from domestic production (47%), and 1% from purchased products (1%).



Source: Prepared by FISCO from the Company's results briefing materials

Shareholder return policy

Pledges a dividend payout ratio of 50% or higher (non-consolidated basis) and forecasts an annual dividend of ¥60.0 per share

The Company's equity ratio reached 89.2% at the end of FY8/22 and it is financially stable. Additionally, considering the Company's business conditions, it seems highly unlikely that its profits will rapidly deteriorate, so continued stable earnings are expected. As a result, if its distribution of earnings outside the Company (particularly dividend payments) is low, profits will accumulate in shareholders' equity each year, and return on equity (ROE) will decline; which is to say, capital efficiency will decline. But in addition to paying dividends commensurate with the growth in profits, the Company actively and comprehensively returns profits to shareholders, including through share buybacks, and as a result has maintained a high ROE (9.0% in FY8/22).

Shareholder return policy

The Company has pledged a dividend payout ratio of 50% or higher on a non-consolidated basis. In FY8/17, it increased the annual dividend from ¥50.0 to ¥60.0, and paid an annual dividend of ¥60.0 each year from FY8/18 to FY8/22. The Company has already announced an annual dividend of ¥60.0 per share for FY8/23 as well. In addition, the Company proactively engages in share buybacks and acquired 612,700 treasury shares (¥1,231mn) and retired 2,500,000 treasury shares in FY8/22 with the objective of enhancing capital efficiency and to respond to the changing management environment. In addition to the Company's strong financial position, this consistent return to shareholders is worthy of recognition.

Trends in the dividend payout ratio* and the total return ratio*

(¥mn)

	Total dividend amount	Share buybacks	Dividend payout ratio*	Total return ratio*
FY8/10	1,127	0	51.4%	51.4%
FY8/11	1,205	226	52.0%	61.7%
FY8/12	1,205	0	55.1%	55.1%
FY8/13	1,541	229	51.3%	58.7%
FY8/14	1,712	0	54.4%	54.4%
FY8/15	3,324	1,500	107.5%	153.8%
FY8/16	1,662	0	52.5%	52.5%
FY8/17	1,994	0	55.2%	55.2%
FY8/18	1,994	0	55.2%	55.2%
FY8/19	1,995	0	58.0%	58.0%
FY8/20	1,971	1,031	57.9%	87.9%
FY8/21	1,971	0	55.0%	55.0%
FY8/22 (E)	1,935	1,231	52.5%	84.9%

*On a non-consolidated basis

Note: The Company executed 1:2 stock splits in FY8/11

Source: Prepared by FISCO from the Company's results briefing materials



Disclaimer

FISCO Ltd. ("FISCO") offer stock price and index information for use under the approval of the Tokyo Stock Exchange, the Osaka Stock Exchange and Nikkei Inc.

This report is provided solely for the purpose of offering information, and is not a solicitation of investment nor any other act or action.

FISCO prepared and published this report based on information which it considered reliable; however, FISCO does not warrant the accuracy, completeness, fitness nor reliability of the contents of this report or the said information.

The issuers' securities, currencies, commodities, securities and other financial instruments mentioned in this report may increase or decrease in value or lose their value due to influence from corporate activities, economic policies, world affairs and other factors. This report does not make any promises regarding any future outcomes. If you use this report or any information mentioned herein, regardless of the purpose therefor, such use shall be made based on your judgment and responsibility, and FISCO shall not be liable for any damage incurred by you as a result of such use, irrespective of the reason.

This report has been prepared at the request of the company subject hereto based on the provision of information by such company through telephone interviews and the like. However, the hypotheses, conclusions and all other contents contained herein are based on analysis by FISCO. The contents of this report are as of the time of the preparation hereof, and are subject to change without notice. FISCO is not obligated to update this report.

The intellectual property rights, including the copyrights to the main text hereof, the data and the like, belong to FISCO, and any revision, reprocessing, reproduction, transmission, distribution or the like of this report and any duplicate hereof without the permission of FISCO is strictly prohibited.

FISCO and its affiliated companies, as well as the directors, officers and employees thereof, may currently or in the future trade or hold the financial instruments or the securities of issuers that are mentioned in this report.

Please use the information in this report upon accepting the above points.

■ For inquiry, please contact: ■

FISCO Ltd.

5-13-3 Minami Aoyama, Minato-ku, Tokyo, Japan 107-0062

Phone: 03-5774-2443 (IR Consulting Business Division)

Email: support@fisco.co.jp